Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...

Karnataka launches 'Kusuma Sanjeevini' program, providing free prophylactic treatment and transport for hemophilia patients, enhancing their quality of life.

The US Food and Drug Administration (FDA) has approved the gene therapy fidanacogene elaparvovec (Beqvez) for adults with hemophilia B, a rare bleeding disorder that affects almost 4 in 100,000 US men ...

Early prophylaxis reduces bone loss in haemophilia, while delayed or absent treatment increases osteoporosis risk.

Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...

(UPDATED) Patients with vulnerable plaques identified with intravascular ultrasound and near-infrared spectroscopy (NIRS) are at a significantly increased risk of major adverse cardiovascular events, ...